GlassScriptPhysician profile
Seth Andrew Kareus
NPI 1639354376
$91,195.22
in general payments reported to CMS, 2019-2025
44 companies · $9,420 in 2025
The $9,420 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $11K · 2021: $16K · 2022: $3,109 · 2023: $20K · 2024: $8,017 · 2025: $9,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $5,178 · Food and Beverage: $2,847 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,437.50 |
| Travel and Lodging | $5,177.94 |
| Food and Beverage | $2,846.65 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $73,086.28 | 2019-2025 | Vercise, General - Dbs |
| Teva Pharmaceuticals USA, INC. | $9,974.02 | 2019-2022 | |
| Allergan, INC. | $3,042.36 | 2019-2022 | |
| Abbvie INC. | $1,131.23 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $483.74 | 2019-2025 | |
| Biogen, INC. | $472.44 | 2020-2025 | Tysabri, Vumerity |
| Abbott Laboratories | $389.42 | 2019-2025 | Infinity |
| Genzyme Corporation | $249.60 | 2019-2023 | |
| Tg Therapeutics, INC. | $230.98 | 2024-2025 | |
| Lilly USA, LLC | $228.60 | 2019-2024 | Amyvid, Kisunla, Reyvow |
| Acorda Therapeutics, INC | $184.26 | 2019-2023 | Inbrija |
| Sunovion Pharmaceuticals INC. | $155.81 | 2019-2022 | |
| Ucb, INC. | $141.72 | 2019-2025 | Briviact, Rystiggo |
| Emd Serono, INC. | $109.44 | 2019-2023 | Mavenclad |
| Genentech USA, INC. | $103.62 | 2019-2023 | Ocrevus, Enspryng |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Kareus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.